What Is Liraglutide? Benefits, Research & Safety
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
UK summary: Licensed UK medicine (Saxenda for weight management; Victoza for type 2 diabetes). Prescription-only. Daily injection; pre-dates and is generally less potent than semaglutide and tirzepatide. Lawful supply requires a UK prescriber and a regulated pharmacy.
Quick Facts
Overview
Liraglutide — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Licensed UK medicine (Saxenda for weight management; Victoza for type 2 diabetes). Prescription-only. Daily injection; pre-dates and is generally less potent than semaglutide and tirzepatide. Lawful supply requires a UK prescriber and a regulated pharmacy.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
- EU: EMA approved for both indications.
- Notes: Liraglutide is a fully approved prescription medication available through legitimate medical channels.
05Approved medical uses
- Type 2 diabetes (Victoza — MHRA-licensed POM).
- Chronic weight management in adults with BMI ≥ 30 or ≥ 27 with weight-related comorbidity (Saxenda — MHRA-licensed POM).
- Chronic weight management in adolescents aged 12-17 with obesity (Saxenda — MHRA-licensed POM).
06Unapproved / promotional claims
- Available without prescription from EU pharmacies.
- Same effect as semaglutide for less money.
- Safe to self-administer without medical supervision.
- Compounded versions are equivalent to the licensed product.
07Common internet claims
- Marketed by online sellers as a cheaper Wegovy alternative.
- Sold via grey-market routes that bypass UK prescription requirements.
- Promoted in 'compounded liraglutide' forms by some online clinics.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved by MHRA for weight management” | A | Yes | Low | Liraglutide is licensed in the UK as Saxenda for chronic weight management in eligible patients; Victoza is licensed for type 2 diabetes. |
| “Same effect as semaglutide for less money” | C | Yes | Moderate | Head-to-head data suggest liraglutide produces less weight loss than semaglutide and requires daily injections rather than weekly. |
| “Available without prescription from EU pharmacies” | E | No | High | Liraglutide is a UK POM; the UK supply route requires a UK prescription and regulated pharmacy. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- GI side effects (nausea, vomiting, diarrhoea) — common, dose-related.
- Pancreatitis (rare; class effect for GLP-1 agonists).
- Gallbladder disease (accelerated by rapid weight loss).
- Thyroid C-cell tumours (theoretical class warning; rodent finding, uncertain human relevance).
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
14EU legal position
EMA approved for both indications.
15What this page cannot tell you
- Whether a non-UK-prescription source supplies genuine, properly-stored product.
- Whether liraglutide is the right GLP-1 for your particular situation (semaglutide / tirzepatide may be preferred).
- Optimal duration and post-discontinuation management.
- Whether 'compounded liraglutide' from an online clinic meets sterility and identity standards.
16Last reviewed
17Citation quality score
18Research gaps
- Long-term cardiovascular outcomes beyond LEADER trial endpoints.
- Optimal weight-management duration and stopping rules.
- Real-world cost-effectiveness against newer GLP-1s in NHS settings.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS specialist or GMC-registered private prescriber where higher efficacy is required.
- Continued lifestyle intervention via NHS Tier 2 weight-management programmes.
- Bariatric assessment for patients meeting NICE criteria.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I better suited to liraglutide or a weekly GLP-1 such as semaglutide?
- What is the dose-escalation schedule and side-effect plan?
- Is NHS access realistic for my situation, or is private the route?
- How will we monitor progress and when would we stop?
- What should I do if I want to stop the medicine?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Improved glycaemic control with HbA1c reductions of 1-1.5%
- 2Weight loss averaging 5-8% of body weight (Saxenda dose)
- 3Reduced cardiovascular events in high-risk patients (LEADER trial)
- 4Decreased systolic blood pressure
- 5Improved beta cell function markers
- 6Reduced appetite and food cravings
- 7Improved lipid profiles
Claim vs Evidence
How popular claims about Liraglutide stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved by MHRA for weight management” | A | Yes | Low | Liraglutide is licensed in the UK as Saxenda for chronic weight management in eligible patients; Victoza is licensed for type 2 diabetes. |
| “Same effect as semaglutide for less money” | C | Yes | Moderate | Head-to-head data suggest liraglutide produces less weight loss than semaglutide and requires daily injections rather than weekly. |
| “Available without prescription from EU pharmacies” | E | No | High | Liraglutide is a UK POM; the UK supply route requires a UK prescription and regulated pharmacy. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Diabetes: 0.6-1.8 mg daily; Obesity: up to 3.0 mg daily |
| Frequency | Once daily subcutaneous injection |
| Duration | Long-term treatment; gradual dose escalation over several weeks |
| Notes | Liraglutide is a prescription medication requiring medical supervision. Doses are typically escalated gradually to minimise gastrointestinal side effects. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (once daily)
| Half-Life | Stability |
|---|---|
| Approximately 13 hours | Pens should be refrigerated before first use; can be kept at room temperature for up to 30 days after first use |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (especially during initiation)
- Vomiting
- Diarrhoea
- Constipation
- Headache
- Decreased appetite
- Injection site reactions
Rare Risks & Concerns
- Pancreatitis
- Gallbladder disease
- Thyroid tumours (based on rodent studies)
- Hypoglycaemia (especially with concurrent insulin or sulfonylureas)
- Acute kidney injury
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- History of pancreatitis
- Pregnancy and breastfeeding
- Type 1 diabetes
UK & EU Regulatory Context
🇬🇧 United Kingdom
MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
🇪🇺 European Union
EMA approved for both indications.
Clinical Studies Summary
LEADER: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Demonstrated 13% reduction in major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Showed 8% weight loss with liraglutide 3.0 mg vs 2.6% with placebo over 56 weeks.
Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.
For individuals with normal weight, both semaglutide and liraglutide are generally more effective for treating T2DM. However, considering the potential for semaglutide to cause hypoglycemia, liraglutide may be the optimal choice for T2DM treatment to minimize the risk of hypoglycemia.
Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.
GLP- 1 agonists such as liraglutide and semaglutide effectively lower body weight and BMI in patients who suffer from weight recurrence or suboptimal clinical response after undergoing MBS. However, future studies are still warranted to investigate the most appropriate protocols for management.
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.
GLP-1 RAs showed several adverse gastrointestinal effects in non-diabetic patients with overweight or obesity. Understanding the different risk profiles of GLP-1 RAs helps clinicians make informed treatment decisions by balancing therapeutic benefits with potential side effects.
Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.
Using GLP-1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.
Registered Trials & Regulatory Status
35 of 66 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Status: Recruiting · 75 participants · Novo Nordisk A/S
Conditions: Obesity
Tirzepatide vs Liraglutide in Bone
Status: Recruiting · 72 participants · National and Kapodistrian University of Athens
Conditions: Obesity (Disorder)
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Status: Recruiting · 430 participants · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: T2DM (Type 2 Diabetes Mellitus)
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
Status: Completed · 10 participants · Nils Opel
Conditions: Healthy
LIROH - Liraglutide for Obesity in HIV
Status: Unknown · 40 participants · Brigham and Women's Hospital
Conditions: Obesity, HIV Infections
The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes
Status: Unknown · 256 participants · Peking University People's Hospital
Conditions: Diabetes Mellitus, Type 2
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery
Status: Completed · 100 participants · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions: Obesity, Weight Loss, Bariatric Surgery
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
Status: Completed · 32 participants · Carmot Therapeutics, Inc.
Conditions: Type 1 Diabetes
A Study of LY3537021 in Healthy Participants
Status: Completed · 47 participants · Eli Lilly and Company
Conditions: Healthy
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
Status: Completed · 35 participants · David Sanchez Garcia
Conditions: Diabetes Mellitus, Type 1
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
Status: Completed · 27 participants · Milton S. Hershey Medical Center
Conditions: Opiate Substitution Treatment, Opioid-Related Disorders
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Status: Completed · 241,981 participants · Kaiser Permanente
Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases
Adverse event reports (FDA FAERS)
- nausea647
- vomiting331
- dyspnoea328
- blood glucose increased326
- diarrhoea321
- anxiety228
- pancreatitis219
- condition aggravated216
- headache215
- drug ineffective209
FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Liraglutide?
Source research-grade Liraglutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Liraglutide
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I better suited to liraglutide or a weekly GLP-1 such as semaglutide?
- What is the dose-escalation schedule and side-effect plan?
- Is NHS access realistic for my situation, or is private the route?
- How will we monitor progress and when would we stop?
- What should I do if I want to stop the medicine?
UK regulatory & safety context
Related Research Guides
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn more